

PRV

PATENT- OCH REGISTRERINGSVERKET
PatentavdelningenIntyg
Certificate

REC'D 05 AUG 2004	
WIPO	PCT

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0401420-5
Patent application number

(86) Ingivningsdatum 2004-06-03
Date of filing

Stockholm, 2004-07-01

För Patent- och registreringsverket
For the Patent- and Registration Office



Juris Rozitis

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

CHEMICAL COMPOUNDS

The present invention relates to heterocyclic derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active piperidine derivatives are disclosed in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514, WO99/04794, WO00/76511, WO00/76512, WO00/76513, WO00/76514, WO00/76972, US 2002/0094989 and Bioorg. Med. Chem. Lett. 13 (2003) 119-123.

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).


Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

The CCR5 receptor is expressed on T-lymphocytes, monocytes, macrophages, dendritic cells, microglia and other cell types. These detect and respond to several chemokines, principally "regulated on activation normal T-cell expressed and secreted" (RANTES), macrophage inflammatory proteins (MIP) MIP-1 α and MIP-1 β and monocyte chemoattractant protein-2 (MCP-2).

This results in the recruitment of cells of the immune system to sites of disease. In many diseases it is the cells expressing CCR5 which contribute, directly or indirectly, to tissue damage. Consequently, inhibiting the recruitment of these cells is beneficial in a wide range of diseases.

CCR5 is also a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Blocking the receptor with a CCR5 antagonist or inducing receptor internalisation with a CCR5 agonist protects cells from viral infection.

The present invention provides a compound of formula (I):



wherein:

A is absent or is (CH₂)₂;

R¹ is C(O)NR¹⁰R¹¹, C(O)₂R¹², NR¹³C(O)R¹⁴, NR¹⁵C(O)NR¹⁶R¹⁷, NR¹⁸C(O)₂R¹⁹, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl, cycloalkyl or heteroaryl; R¹⁰, R¹³, R¹⁵, R¹⁶ and R¹⁸ are hydrogen or C₁₋₆ alkyl;

R¹¹, R¹², R¹⁴, R¹⁷ and R¹⁹ are C₁₋₈ alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl (optionally substituted by halo), C₅₋₆ cycloalkenyl, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C₃₋₇ cycloalkyl (optionally substituted by halo or C₁₋₄ alkyl), C₄₋₇ cycloalkyl fused to a phenyl ring, C₅₋₇ cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C₁₋₆ alkyl), S(O)_k(C₁₋₆ alkyl), halo or C₁₋₄ alkyl); or R¹¹, R¹², R¹⁴ and R¹⁷ can also be hydrogen;

or R¹⁰ and R¹¹, and/or R¹⁶ and R¹⁷ may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C₁₋₆ alkyl, S(O)_l(C₁₋₆ alkyl) or C(O)(C₁₋₆ alkyl);

R² is phenyl, heteroaryl or C₃₋₇ cycloalkyl;

R³ is H or C₁₋₄ alkyl;

X is S(O)₂NR⁴R⁵ or NR⁶S(O)₂R⁷;

R⁷ is aryl, heteroaryl, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, heterocyclyl or NR⁸R⁹ wherein NR⁸R⁹ can be cyclized to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C₁₋₆ alkyl, S(O)_p(C₁₋₆ alkyl) or C(O)(C₁₋₆ alkyl);

R⁴ and R⁸ are aryl, heteroaryl, C₁₋₆ alkyl, C₃₋₇ cycloalkyl or heterocyclyl;

R⁵, R⁶ and R⁹ are, independently, hydrogen or C₁₋₆ alkyl;

n is 1, 2 or 3;

10 aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR²⁰R²¹, NR²²R²³, NR²⁴C(O)R²⁵, NR²⁶C(O)NR²⁷R²⁸, S(O)₂NR²⁹R³⁰, NR³¹S(O)₂R³², C(O)NR³³R³⁴, CO₂R³⁶, NR³⁷CO₂R³⁸, S(O)_qR³⁹, OS(O)₂R⁴⁹, C₁₋₆ alkyl (optionally mono-substituted by S(O)₂R⁵⁰ or C(O)NR⁵¹R⁵²), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)₂, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), 20 C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), CF₃ or OCF₃;

25 unless otherwise stated heterocyclyl is optionally substituted by C₁₋₆ alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)} or heteroaryl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}], phenyl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}, heteroaryl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}, 30 S(O)₂NR⁴⁰R⁴¹, C(O)R⁴², C(O)₂(C₁₋₆ alkyl) (such as tert-butoxycarbonyl), C(O)₂(phenyl(C₁₋₂ alkyl)) (such as benzyloxycarbonyl), C(O)NHR⁴³, S(O)₂R⁴⁴, NHS(O)₂NHR⁴⁵, NHC(O)R⁴⁶,

NHC(O)NHR⁴⁷ or NHS(O)₂R⁴⁸, provided none of these last four substituents is linked to a ring nitrogen;

k, l, p and q are, independently, 0, 1 or 2;

R²⁰, R²², R²⁴, R²⁶, R²⁷, R²⁹, R³¹, R³³, R³⁷, R⁴⁰ and R⁵¹ are, independently, hydrogen or C₁₋₆ alkyl;

R²¹, R²³, R²⁵, R²⁸, R³⁰, R³², R³⁴, R³⁶, R³⁸, R³⁹, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰ and R⁵² are, independently, C₁₋₆ alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkenyl, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), heteroaryl, phenyl, heteroaryloxy or phenoxy), C₃₋₇ cycloalkyl, phenyl or heteroaryl;

wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;

R²¹, R²³, R²⁵, R²⁸, R³⁰, R³⁴, R³⁵, R³⁶, R⁴¹, R⁴², R⁴³, R⁴⁵, R⁴⁶, R⁴⁷ and R⁵² may additionally be hydrogen;

or a pharmaceutically acceptable salt thereof or a solvate thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

Alkyl groups and moieties are straight or branched chain and, for example, comprise one to six (such as one to four) carbon atoms. Alkyl is, for example, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl or *tert*-butyl. Methyl is sometimes abbreviated to Me hereinbelow.

30 Haloalkyl includes CF₃, and haloalkoxy includes OCF₃.

Fluoroalkyl includes, for example, one to six, such as one to three, fluorine atoms, and comprises, for example, a CF₃ group. Fluoroalkyl is, for example, CF₃ or CH₂CF₃.

Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl (such as cyclohexyl). Cycloalkenyl includes cyclopentenyl.

Heterocyclyl is linked by a ring-carbon or ring-heteroatom (such as a ring-nitrogen), and is, for example, piperidine, piperazine, pyrrolidine, azetidine, tetrahydrofuran, morpholine or thiomorpholine.

5 Aryl includes phenyl and naphthyl. In one aspect of the invention aryl is phenyl.

Heteroaryl is, for example, an aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof.

10 Heteroaryl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, [1,2,4]-triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as 15 imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxaliny, a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), quinolinyl, isoquinolinyl, a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl), a benzothiazinyl or dibenzothiophenyl (also known as dibenzothienyl); 20 or an N-oxide thereof, or an S-oxide or S-dioxide thereof.

Aryloxy includes phenoxy.

Heteroaryloxy includes pyridinyloxy and pyrimidinyloxy.

Phenyl(C₁₋₄ alkyl)alkyl is, for example, benzyl, 1-(phenyl)eth-1-yl or 1-(phenyl)eth-2-yl.

25 Heteroaryl(C₁₋₄ alkyl)alkyl is, for example, pyridinylmethyl, pyrimidinylmethyl or 1-(pyridinyl)eth-2-yl.

Phenyl(C₁₋₄ alkoxy) is, for example, benzyloxy or phenylCH(CH₃)O.

Heteroaryl(C₁₋₄ alkoxy) is, for example, pyridinylCH₂O, pyrimidinylCH₂O or pyridinylCH(CH₃)O.

30 Heteroaryl rings can carry various substituents including sulphonyl groups. A sulphonyl group on a heteroaryl ring can be a good leaving group (susceptible to nucleophilic displacement) and examples of such situation are: 2-methanesulphonyl-pyridine and 2- or 4-methanesulphonyl-pyrimidine. The present invention covers compounds including a

heteroaryl ring carrying a sulphonyl group which are sufficiently stable (non-reactive) to be isolated using the experimental procedures described.

In one particular aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, $S(C_{1-4} \text{ alkyl})$, $S(O)(C_{1-4} \text{ alkyl})$, $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2\text{NH}_2$, $S(O)_2\text{NH}(C_{1-4} \text{ alkyl})$, $S(O)_2\text{N}(C_{1-4} \text{ alkyl})_2$, cyano, $C_{1-4} \text{ alkyl}$, $C_{1-4} \text{ alkoxy}$, $C(O)\text{NH}_2$, $C(O)\text{NH}(C_{1-4} \text{ alkyl})$, CO_2H , $\text{CO}_2(C_{1-4} \text{ alkyl})$, $\text{NHC}(O)(C_{1-4} \text{ alkyl})$, $\text{NHS}(O)_2(C_{1-4} \text{ alkyl})$, CF_3 , CHF_2 , CH_2F , CH_2CF_3 , OCF_3 or tetrazolyl (optionally substituted by $C_{1-4} \text{ alkyl}$).

10 In a further aspect of the invention heteroaryl is pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl.

In another aspect of the invention R^{10} , R^{13} , R^{15} , R^{16} and R^{18} are hydrogen or $C_{1-4} \text{ alkyl}$ (for example methyl). In yet another aspect R^{10} , R^{13} , R^{15} , R^{16} and R^{18} are hydrogen.

15 In a further aspect of the invention R^{11} , R^{12} , R^{14} , R^{17} , R^{18} and R^{19} are $C_{1-8} \text{ alkyl}$ (optionally substituted by halo, $C_{1-6} \text{ alkoxy}$, $C_{1-6} \text{ haloalkoxy}$, $C_{3-6} \text{ cycloalkyl}$ (optionally substituted by halo), $C_{5-6} \text{ cycloalkenyl}$, $S(O)_2(C_{1-4} \text{ alkyl})$, heteroaryl, phenyl, heteroaryloxy or aryloxy (for example phenoxy)), phenyl, heteroaryl, $C_{3-7} \text{ cycloalkyl}$ (optionally substituted by halo or $C_{1-4} \text{ alkyl}$), $C_{4-7} \text{ cycloalkyl}$ fused to a phenyl ring, $C_{5-7} \text{ cycloalkenyl}$, or, heterocyclyl (itself optionally substituted by oxo, $C(O)(C_{1-6} \text{ alkyl})$, $S(O)_k(C_{1-4} \text{ alkyl})$, halo or $C_{1-4} \text{ alkyl}$); k is 0, 1 or 2; or R^{10} and R^{11} , and/or R^{16} and R^{17} may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by $C_{1-6} \text{ alkyl}$, $S(O)_2(C_{1-4} \text{ alkyl})$ or $C(O)(C_{1-6} \text{ alkyl})$.

20 In yet another aspect of the invention R^{11} , R^{12} , R^{14} , R^{17} and R^{19} are $C_{1-8} \text{ alkyl}$ (optionally substituted by halo (such as fluoro)), phenyl (optionally substituted as recited above), $C_{3-6} \text{ cycloalkyl}$ (optionally substituted by halo (such as fluoro)) or C-linked nitrogen containing heterocyclyl (optionally substituted on the ring nitrogen).

25 In another aspect of the invention R^1 is $NR^{13}\text{C}(O)\text{R}^{14}$, wherein R^{13} and R^{14} are as defined above.

30 In yet another aspect of the invention R^{14} is $C_{1-8} \text{ alkyl}$ (optionally substituted by halo (such as fluoro, for example to form CF_3CH_2)), phenyl (optionally substituted as recited above), $C_{3-6} \text{ cycloalkyl}$ (optionally substituted by halo (such as fluoro, for example to form 1,1-difluorocyclohex-4-yl)) or C-linked nitrogen containing heterocyclyl (such as pyran or piperidine, optionally substituted on the ring nitrogen).

In another aspect the present invention provides a compound of the invention wherein R¹⁴ is C₁₋₈ alkyl (optionally substituted by halo (such as fluoro, for example to form CF₃CH₂)), phenyl (optionally substituted by halo) or C₅₋₆ cycloalkyl (optionally substituted by halo (such as fluoro, for example to form 1,1-difluorocyclohex-4-yl)).

5 In a further aspect of the invention heterocyclyl is optionally substituted (such as singly substituted for example on a ring nitrogen atom when present) by C₁₋₆ alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio or S(O)₂(C₁₋₄ alkyl)} or heteroaryl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, 10 CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio or S(O)₂(C₁₋₄ alkyl)}], phenyl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio or S(O)₂(C₁₋₄ alkyl)}, heteroaryl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio or S(O)₂(C₁₋₄ alkyl)}, S(O)₂NR⁴⁰R⁴¹, C(O)R⁴², C(O)NHR⁴³ or S(O)₂R⁴⁴; wherein R⁴⁰, R⁴¹, R⁴² 15 and R⁴³ are, independently, hydrogen or C₁₋₆ alkyl; and R⁴⁴ is C₁₋₆ alkyl.

In yet another aspect of the invention R¹ is optionally substituted aryl (such as optionally substituted phenyl) or optionally substituted heteroaryl, wherein the optional substituents are as recited above.

20 In a further aspect of the invention R¹ is optionally substituted heterocyclyl, such as optionally substituted: piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, azetidin-1-yl or azetidin-3-yl.

25 In a still further aspect of the invention the heterocyclyl of R¹ is mono-substituted by C₁₋₆ alkyl, C₃₋₇ cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), C₁₋₄ alkyl (for example methyl), C₁₋₄ alkoxy (for example methoxy), CF₃ or OCF₃}, S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃, S(O)₂CH₂CH₃ or S(O)₂CH(CH₃)₂), S(O)₂(C₁₋₄ fluoroalkyl) (for example S(O)₂CF₃ or S(O)₂CH₂CF₃), S(O)₂phenyl {optionally substituted (such as mono-substituted) by halo (for example chloro), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃ or S(O)₂CH₂CH₂CH₃) or S(O)₂(C₁₋₄ fluoroalkyl) (for example S(O)₂CH₂CF₃)}, benzyl {optionally substituted by halo (for example chloro or fluoro), C₁₋₄ alkyl, C₁₋₄ alkoxy (for example methoxy), CF₃ or OCF₃}, C(O)H, C(O)(C₁₋₄ alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), C₁₋₄ alkyl (for example methyl), C₁₋₄ alkoxy, CF₃ or OCF₃}, C(O)₂(C₁₋₄ alkyl), C(O)NH₂, C(O)NH(C₁₋₄ alkyl) or C(O)NHphenyl {optionally substituted by halo (for example fluoro), C₁₋₄ alkyl, C₁₋₄ alkoxy,

CF₃ or OCF₃}. Said heterocyclyl can also be mono-substituted by S(O)₂NH₂ and S(O)₂N(C₁₋₄ alkyl)₂. In a still further aspect when said heterocyclyl is a 4-substituted piperidin-1-yl, a 1-substituted piperidin-4-yl, a 4-substituted piperazin-1-yl, a 3-substituted pyrrolidin-1-yl, a 1-substituted pyrrolidin-3-yl, a 3-substituted azetidin-1-yl or a 1-substituted azetidin-3-yl (for example where said substituent is as recited earlier in this paragraph). In another aspect said heterocyclyl is a 1-substituted piperidin-4-yl or a 4-substituted piperazin-1-yl, wherein the substituent is S(O)₂(C₁₋₄ alkyl), S(O)₂(C₁₋₄ haloalkyl), S(O)₂(phenyl), S(O)₂N(C₁₋₄ alkyl)₂ or phenyl.

In yet another aspect of the invention R² is phenyl or heteroaryl, either of which is optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_n(C₁₋₄ alkyl), nitro, cyano or CF₃; wherein n is 0, 1 or 2, for example 0 or 2. When R² is heteroaryl it is, for example an optionally substituted thiophenyl.

In a still further aspect R² is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF₃), or optionally substituted (for example unsubstituted or mono-substituted) heteroaryl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF₃).

In another aspect the invention provides a compound of the invention wherein R² is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (for example chloro or fluoro)). In yet another aspect the invention provides a compound of the invention wherein R² is phenyl, 3-fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 3-chloro-5-fluorophenyl or 3,5-difluorophenyl. In a further aspect the invention provides a compound of the invention wherein R² is phenyl, 3-fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl or 3,5-difluorophenyl.

In yet another aspect of the invention R³ is hydrogen or methyl. In a further aspect of the invention when R³ is C₁₋₄ alkyl (such as methyl) and the carbon to which R³ is attached has the R absolute configuration. In yet another aspect of the invention R³ is hydrogen.

In another aspect of the invention X is NR⁶S(O)₂R⁷.

In a further aspect of the invention X is S(O)₂NR⁴R⁵.

In a still further aspect the present invention provides a compound of the invention wherein R⁴, R⁷ and R⁸ are optionally substituted phenyl (the optional substituents being selected from those recited above), optionally substituted benzyl (the phenyl ring being

optionally substituted, the substituents being selected from those recited above) or optionally substituted heteroaryl (such as pyridyl, imidazolyl or 1,3,4-thiadiazolyl) (the optional substituents being selected from those recited above).


In yet another aspect the present invention provides a compound of the invention
 5 wherein R⁴, R⁷ and R⁸ are phenyl or heteroaryl, each being optionally substituted by OS(O)₂R⁴⁹ or C₁₋₆ alkyl (mono-substituted by S(O)₂R⁵⁰ or C(O)NR⁵¹R⁵²); wherein R⁴⁹, R⁵⁰, R⁵¹ and R⁵² are as defined above, and phenyl may also be substituted by tetrazolyl (itself optionally substituted by C₁₋₄ alkyl).

In a further aspect the present invention provides a compound of the invention wherein
 10 R⁴ is phenyl (optionally substituted, for example in the para-position, by halogen (such as chloro or fluoro), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), OS(O)₂(C₁₋₄ alkyl) or carboxamide), C₃₋₇ cycloalkyl (such as cyclohexyl), pyridyl (optionally substituted by C₁₋₄ alkyl), imidazolyl (optionally substituted by C₁₋₄ alkyl) or 1,3,4-thiadiazolyl (optionally substituted by C₁₋₄ alkyl).

15 In a still further aspect the invention provides a compound of the invention wherein A is absent.

In a still further aspect the invention provides a compound of the invention wherein p is 0.

In a still further aspect the present invention provides a compound of formula (Ia):




20 wherein Y is CH or N; R^{1a} is mono-substituted by C₁₋₆ alkyl, C₃₋₇ cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), C₁₋₄ alkyl (for example methyl), C₁₋₄ alkoxy (for example methoxy), CF₃ or OCF₃}, S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃, S(O)₂CH₂CH₃ or S(O)₂CH(CH₃)₂), S(O)₂(C₁₋₄ fluoroalkyl) (for example S(O)₂CF₃ or S(O)₂CH₂CF₃), S(O)₂phenyl {optionally substituted (such as mono-substituted) by halo (for example chloro), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, S(O)₂(C₁₋₄ alkyl) (for example


S(O)₂CH₃ or S(O)₂CH₂CH₂CH₃) or S(O)₂(C₁₋₄ fluoroalkyl) (for example S(O)₂CH₂CF₃), benzyl {optionally substituted by halo (for example chloro or fluoro), C₁₋₄ alkyl, C₁₋₄ alkoxy (for example methoxy), CF₃ or OCF₃}, C(O)H, C(O)(C₁₋₄ alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), C₁₋₄ alkyl (for example methyl), C₁₋₄ alkoxy, CF₃ or OCF₃}, C(O)₂(C₁₋₄ alkyl), C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N_{Phenyl} {optionally substituted by halo (for example fluoro), C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃ or OCF₃} or S(O)₂N(C₁₋₄ alkyl)₂; R^{2a} and R^{2b} are, independently, hydrogen or halo (for example fluoro); and R⁷ is phenyl {optionally substituted by halo (for example fluoro and chloro), C₁₋₄ alkyl (for example methyl), C₁₋₄ alkoxy (for example methoxy), S(O)₂(C₁₋₄ alkyl) (for example 5

10 S(O)₂CH₃, S(O)₂(C₁₋₄ fluoroalkyl) (for example S(O)₂CF₃), NH(CO)(C₁₋₄ alkyl) (for example NH(C(O))Me), NH(S(O)₂)(C₁₋₄ alkyl) (for example NH(S(O)₂)Me), NH(S(O)₂)(C₁₋₄ fluoroalkyl) (for example NH(S(O)₂)CF₃), 4-nitrophenyl or 4-cyanophenyl.

In a further aspect the present invention provides a compound of formula (Ib):




15 In a still further aspect the present invention provides a compound of formula (Ic):



wherein R^{1b} is halo, hydroxy, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), CF₃, CHF₂, CH₂F, CH₂CF₃ or OCF₃; and R^{2a}, R^{2b} and R⁷ are as defined above.

20 In another aspect the present invention provides a compound of formula (Id):



wherein R^{1b} , R^{2a} , R^{2b} and R^7 are as defined above.

In yet another aspect of the invention there is provided a compound of formula (Ia), (Ib), (Ic) or (Id) {for example a compound of formula (Ia), (Ib) or (Ic)} wherein R^{2a} and R^{2b} are, independently, hydrogen, halo (such as chloro or fluoro) or CF_3 .

In a still further aspect of the invention there is provided a compound of formula (I), (Ia), (Ib) or (Ic) wherein R^7 is phenyl substituted by $S(O)_2(C_{1-4}$ alkyl) (for example $CH_3S(O)_2$), CN , NH_2 , $(C_{1-4}$ alkyl) $S(O)_2NH$ (for example $CH_3S(O)_2NH$), $(C_{1-4}$ alkyl) $C(O)NH$ (for example $CH_3C(O)NH$), C_{1-4} alkoxy (for example CH_3O), $(C_{1-4}$ alkyl) $S(O)_2O$ (for example $CH_3S(O)_2O$) or tetrazolyl substituted by C_{1-4} alkyl (for example 1-methyltetrazol-5-yl or 2-methyltetrazol-5-yl).

In another aspect of the invention there is provided a compound of formula (I), (Ia), (Ib) or (Ic) wherein R^7 is C_{1-4} alkyl (such as methyl), di(C_{1-4} alkyl)amino (such as dimethylamino) or phenyl (the phenyl being optionally substituted by: halogen (such as chloro or fluoro), nitro, cyano, C_{1-4} alkyl (such as methyl), $S(O)_2(C_{1-4}$ alkyl) (for example $CH_3S(O)_2$), $(C_{1-4}$ alkyl) $S(O)_2NH$ (for example $CH_3S(O)_2NH$) or (C_{1-4} haloalkyl) $S(O)_2NH$ (for example $CF_3S(O)_2NH$).

In yet another aspect the present invention provides a compound of formula (I) wherein n is 1 or 2; A is absent; R^1 is phenyl {optionally substituted by $S(O)_2(C_{1-4}$ alkyl) (for example $CH_3S(O)_2$)} or piperidin-4-yl {optionally substituted, for example on the 1-position, by $S(O)_2(C_{1-4}$ alkyl) (for example $CH_3S(O)_2$)}; R^2 is phenyl optionally substituted by halogen (for example fluoro, such as 3-fluoro or 3,5-difluoro); R^3 is hydrogen; X is $NHS(O)_2R^7$; and R^7 is C_{1-4} alkyl (for example methyl), di(C_{1-4} alkyl)amino (for example dimethylamino), phenyl {optionally substituted by: halogen (such as chloro or fluoro), nitro, cyano, amino, C_{1-4} alkyl (such as methyl), C_{1-4} haloalkyl (for example CF_3), C_{1-4} alkoxy (such as methoxy), phenoxy, $S(O)_2(C_{1-4}$ alkyl) (for example $CH_3S(O)_2$), $(C_{1-4}$ alkyl) $S(O)_2NH$ (for example


$\text{CH}_3\text{S(O)}_2\text{NH}$, $(\text{CH}_3)_2\text{CHS(O)}_2\text{NH}$ or $(\text{CH}_3)_3\text{CS(O)}_2\text{NH}$, $(\text{C}_{1-4} \text{ haloalkyl})\text{S(O)}_2\text{NH}$ (for example $\text{CF}_3\text{S(O)}_2\text{NH}$), $(\text{C}_{1-4} \text{ alkyl})\text{C(O)NH}$ (for example $\text{CH}_3\text{C(O)NH}$) or tetrazolyl}, thienyl {optionally substituted by pyridinyl} or pyridinyl.

The compounds listed in Tables I, II and III illustrate the invention.

5

Table I

Table I comprises compounds of formula (Ia)




Compound No	R ^{1a}	R ^{2a}	R ^{2b}	Y	R'	MS (MH ⁺)
1	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4- $\text{S(O)}_2\text{CH}_3$ -phenyl	648
2	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-nitrophenyl	615
3	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-aminophenyl	585
4	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-acetamidophenyl	627
5	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-methanesulphonylaminophenyl	663
6	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-methoxyphenyl	600
7	$\text{S(O)}_2\text{CH}_3$	F	F	CH	3,4-dimethoxyphenyl	630
8	$\text{S(O)}_2\text{CH}_3$	F	F	CH	4-phenoxyphenyl	662

10
11
12
13
14
15
16
17
18
19
20

Table II

Table II comprises compounds of formula (Ic)




Compound No	R ^{1b}	R ^{2a}	R ^{2b}	R ⁷	MS (MH ⁺)
1	S(O) ₂ CH ₃	F	F	4-methanesulphonylphenyl	
2	S(O) ₂ CH ₃	F	F	methyl	
3	S(O) ₂ CH ₃	F	F	dimethylamino	
4	S(O) ₂ CH ₃	F	F	4-methylphenyl	
5	S(O) ₂ CH ₃	F	F	4-nitrophenyl	
6	S(O) ₂ CH ₃	F	F	2-fluorophenyl	
7	S(O) ₂ CH ₃	F	F	3-fluorophenyl	
8	S(O) ₂ CH ₃	F	F	4-fluorophenyl	
9	S(O) ₂ CH ₃	F	F	2,4-difluorophenyl	
10	S(O) ₂ CH ₃	F	F	2-chlorophenyl	
11	S(O) ₂ CH ₃	F	F	3-chlorophenyl	
12	S(O) ₂ CH ₃	F	F	4-chlorophenyl	
13	S(O) ₂ CH ₃	F	F	4-cyanophenyl	
14	S(O) ₂ CH ₃	F	F	4-aminophenyl	
15	S(O) ₂ CH ₃	F	F	4-methanesulphonylaminophenyl	
16	S(O) ₂ CH ₃	F	F	4-trifluoromethylsulphonylaminophenyl	
17	S(O) ₂ CH ₃	F	F	3-cyanophenyl	588
18	S(O) ₂ CH ₃	F	F	3-(5-tetrazolyl)phenyl	631
19	S(O) ₂ CH ₃	F	F	4-(5-tetrazolyl)phenyl	631
20	S(O) ₂ CH ₃	F	F	2-thienyl	569
21	S(O) ₂ CH ₃	F	F	3-pyridyl	564
22	S(O) ₂ CH ₃	F	F	4-acetamidophenyl	620

23	$\text{S(O)}_2\text{CH}_3$	F	F	4-amino-3-chlorophenyl	612
24	$\text{S(O)}_2\text{CH}_3$	F	F	5-(2-pyridyl)-thien-2-yl	646
25	$\text{S(O)}_2\text{CH}_3$	F	F	4-nitro-2-methoxyphenyl	638
26	$\text{S(O)}_2\text{CH}_3$	F	F	4-amino-2-methoxyphenyl	608
27	$\text{S(O)}_2\text{CH}_3$	F	F	2-methoxy-4-methanesulphonylphenyl	686
28	$\text{S(O)}_2\text{CH}_3$	F	F	2-methoxy-4-acetamidophenyl	652
29	$\text{S(O)}_2\text{CH}_3$	F	F	2-methoxy-4-isopropylamidophenyl	678
30	$\text{S(O)}_2\text{CH}_3$	F	F	2-methoxy-4- <i>tert</i> -butylamidophenyl	692
31	$\text{S(O)}_2\text{CH}_3$	F	F	3,4-difluorophenyl	599
32	$\text{S(O)}_2\text{CH}_3$	F	F	4-amino-3-trifluoromethylphenyl	646
33	$\text{S(O)}_2\text{CH}_3$	F	F	4-isopropylamido-3-trifluoromethylphenyl	716

Table III

Table III comprises compounds of formula (Id)




Compound No	R^{1b}	R^{2a}	R^{2b}	R^7	MS (MH+)
1	$\text{S(O)}_2\text{CH}_3$	F	F	methyl	515
2	$\text{S(O)}_2\text{CH}_3$	F	F	4-methanesulphonylphenyl	655
3	$\text{S(O)}_2\text{CH}_3$	F	F	4-nitrophenyl	622
4	$\text{S(O)}_2\text{CH}_3$	F	F	4-aminophenyl	592
5	$\text{S(O)}_2\text{CH}_3$	F	F	4-methanesulphonylaminophenyl	670

5

In yet another aspect the invention provides each individual compound listed in the tables above.


The compounds of formula (I), (Ia), (Ib), (Ic) and (Id) are all compounds of the invention can be prepared as shown below.

A compound of the invention wherein R¹ is an N-linked optionally substituted heterocycle can be prepared by reacting a compound of formula (II):




wherein R², R³, R⁴, m, n, A and X are as defined above, with a compound R¹H (wherein the H is on a heterocycle ring nitrogen atom) wherein R¹ is as defined above, in the presence of a suitable base (for example a tri(C₁₋₆ alkyl)amine such as triethylamine or Hunig's base), in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) and, for example, at a room temperature (for example 10-30°C), optionally in the presence of sodium iodide.

10 A compound of the invention, wherein R³ is hydrogen, can be prepared by coupling a compound of formula (III):




15 15 wherein R⁴, m, n, A and X are as defined above, with a compound of formula (IV):




wherein R¹ and R² are as defined above, in the presence of NaBH(OAc)₃ (wherein Ac is C(O)CH₃) in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) at room temperature (for example 10-30°C).

20 A compound of the invention, wherein R³ is hydrogen, can be prepared by coupling a compound of formula (III):



wherein R⁴, m, n, A and X are as defined above, with a compound of formula (V):

16



wherein R^1 and R^2 are as defined above and L is a leaving group such as halogen, tosylate, mesylate or triflate, in the presence of a base, such as potassium carbonate, in a suitable solvent (such as dioxane, acetonitrile or isopropanol) at temperatures from 60°C up to the 5 boiling point of the solvent.

Alternatively, compounds of the invention can be prepared according to Schemes 1-7 (below).

Alternatively, compounds of the invention can be prepared by using or adapting methods described in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514, 10 WO99/04794, WO00/76511, WO00/76512, WO00/76513, WO00/76514, WO00/76972 or US 2002/0094989.

The starting materials for these processes are either commercially available or can be prepared by literature methods, adapting literature methods or by following or adapting Methods herein described.

15 In a still further aspect the invention provides processes for preparing the compounds of formula (I), (Ia), (Ib) and (Ic). Many of the intermediates in the processes are novel and these are provided as further features of the invention.

20 The compounds of the invention have activity as pharmaceuticals, in particular as modulators (such as agonists, partial agonists, inverse agonists or antagonists) of chemokine receptor (such as CCR5) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

25 The compounds of the present invention are also of value in inhibiting the entry of viruses (such as human immunodeficiency virus (HIV)) into target cells and, therefore, are of value in the prevention of infection by viruses (such as HIV), the treatment of infection by viruses (such as HIV) and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS).

30 According to a further feature of the invention there is provided a compound of the formula (I), (Ia), (Ib) and (Ic), or a pharmaceutically acceptable salt thereof or a solvate

thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (such as CCR5 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof or a solvate thereof.

The present invention also provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, as a medicament, such as a medicament for the treatment of transplant rejection, respiratory disease, psoriasis or rheumatoid arthritis (such as rheumatoid arthritis). [Respiratory disease is, for example, COPD, asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)} or rhinitis {acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}; and is particularly asthma or rhinitis].

In another aspect the present invention provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).

The invention also provides a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament, such as a medicament for the treatment of rheumatoid arthritis.

In another aspect the present invention provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).

The invention further provides the use of a compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma (such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); bronchitis (such as eosinophilic bronchitis); acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa;
- 5 (10) membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polypsis; fibroid lung or idiopathic interstitial pneumonia;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- 15 (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- 20 (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- 25 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridental disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;

in a warm blooded animal, such as man.

The present invention further provides a method of treating a chemokine mediated disease state (such as a CCR5 mediated disease state) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of 5 a compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or solvate thereof.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR5 receptor) activity, said 10 ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a 15 pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 20 to 70 %w, such as from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these 25 purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral 30 administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of active ingredient.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01mgkg^{-1} to 100mgkg^{-1} of the compound, for example in the range of 0.1mgkg^{-1} to 5 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 10 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvent thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

15

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

5 (e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β -cyclodextrin may be used to aid formulation.

10

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

15 The invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, is administered concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a compound of the invention can be combined with a TNF- α inhibitor (such as an anti-TNF monoclonal antibody (such as Remicade, CDP-870 and D.sub2.E.sub7.), or a TNF receptor 5 immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-1 / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), a COX-2 inhibitor (such as meloxicam, celecoxib, rofecoxib, valdecoxib or etoricoxib) low dose 10 methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine or auranofin, or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the invention together with:

- a leukotriene biosynthesis inhibitor, a 5-lipoxygenase (5-LO) inhibitor or a 5-lipoxygenase activating protein (FLAP) antagonist, such as zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761, an N-(5-substituted)-thiophene-2-alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, MK-886 or BAY x 1005;
- a receptor antagonist for a leukotriene LTB₄, LTC₄, LTD₄ or LTE₄ selected from the group consisting of a phenothiazin-3-one such as L-651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BIIL 284/260; or a compound such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A) or BAY x 7195;
- a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
- an antihistaminic H₁ receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine;
- a gastroprotective H₂ receptor antagonist;
- an α .sub1.- and α .sub2.-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine,

naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline

hydrochloride, xylometazoline hydrochloride or ethynorepinephrine hydrochloride;

- an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
- 5 • a β .sub1.- to β .sub4.-adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate or pирbutерол, or a methylxanthanine including theophylline and aminophylline; sodium cromoglycate; or a muscarinic receptor (M1, M2, and M3) antagonist;
- 10 • an insulin-like growth factor type I (IGF-1) mimetic;
- an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate or mometasone furoate;
- an inhibitor of a matrix metalloprotease (MMP), such as a stromelysin, a collagenase, 15 or a gelatinase or aggrecanase; such as collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) or MMP-12;
- a modulator of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family;
- 20 • an osteoporosis agent such as roloxi芬e, droloxi芬e, lasofoxi芬e or fosomax;
- an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate; or,
- 25 • an existing therapeutic agent for the treatment of osteoarthritis, for example a non-steroidal anti-inflammatory agent (hereinafter NSAID's) such as piroxicam or diclofenac, a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen, a fenamate such as mefenamic acid, indomethacin, sulindac or apazone, a pyrazolone such as phenylbutazone, a salicylate such as aspirin, a COX-2 inhibitor such as celecoxib, valdecoxib, rofecoxib or etoricoxib, an analgesic or intra-articular therapy such as a corticosteroid or a hyaluronic acid such as hyalgan or synvisc, or a P2X7 receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin-B._{sub1}. - and B._{sub2}. -receptor antagonist; (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinpyrazone or benzboromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGF β); (xv) a platelet-derived growth factor (PDGF); (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a Tachykinin NK._{sub1}. and NK._{sub3}. receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) an elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) a TNF α converting enzyme inhibitor (TACE); (xxii) an induced nitric 10 oxide synthase inhibitor (iNOS); or (xxiii) a chemoattractant receptor-homologous molecule 15 expressed on TH2 cells (a CTRH2 antagonist).

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or 20 ambient temperature, that is, at a temperature in the range of 18-25°C;
- (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
- (iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin 25 layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI". Where an "Isolute™ SCX column" is referred to, this means a column containing 30 benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where "Argonaut™ PS-tris-amine scavenger resin" is referred to, this means a *tris*-(2-

aminoethyl)amine polystyrene resin obtained from Argonaut Technologies Inc., 887 Industrial Road, Suite G, San Carlos, California, USA.

(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;

5 (v) yields, when given, are for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;

(vi) when given, ^1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio DMSO (CD_3SOCD_3) as the solvent unless otherwise stated; coupling constants (J) are given in Hz;

10 (vii) chemical symbols have their usual meanings; SI units and symbols are used;

(viii) solvent ratios are given in percentage by volume;

(ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;

15 (x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;

20 (xi) PS-NCO resin is an isocyanate resin and is available from Argonaut; and,

(xii) the following abbreviations are used:


THF	tetrahydrofuran
DMSO	dimethylsulphoxide
Boc	<u>tert</u> -butoxycarbonyl
DMF	N,N -dimethylformamide
DCM	dichloromethane
DIPEA	N,N -Diisopropylethylamine

R-BINAP

R 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl


Example 1

5 This Example illustrates the preparation of *N*-[(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}piperidin-4-yl)methyl]-4-(methylsulphonyl)-benzenesulphonamide - methane (Compound 1, Table III)



10 4-Methanesulphonylbenzenesulphonyl chloride (135 mg) was added to a solution of *N*-[(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}piperidin-4-yl)methylamine dihydrochloride (250 mg) and triethylamine (162 mg) in dichloromethane (10 ml) and the mixture was stirred at 20°C for 16 hours. The reaction mixture was washed with water (2x 10 ml), dried and evaporated to dryness. The residue was passed down a Bond Elut column eluting with a solvent gradient (ethyl acetate-30%methanol/ethyl acetate) to give the title compound, yield 176 mg. MH^+ 641. NMR (DMSO_d6): 1.02 (q, 2H), 1.29 (m, 1H), 1.55 (d, 2H), 1.73 (t, 2H), 2.03-2.27 (m, 3H), 2.6-2.78 (m, 3H), 3.27 (s, 6H), 4.17 (t, 1H), 7.0 (m, 1H), 7.10 (d, 2H), 7.6 (d, 2H), 7.80 (m, 3H), 8.0 (d, 2H), 8.13 (d, 2H).

15 [(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}piperidin-4-yl)methylamine dihydrochloride




20 *tert*-Butyl [(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}piperidin-4-yl)methyl]carbamate (1.6g) was dissolved in 4M HCl/dioxane (20 ml) and allowed to stand at room temperature for 2 hours. Diethyl ether (100 ml) was added and the solid obtained was filtered and dried, yield 1.4g. NMR (DMSO_d6): 1.58 (m, 1H), 1.70-2.12

(m, 2H), 2.56-2.75 (m, 4H), 2.76-2.96 (m, 4H), 3.17 (s, 3H), 3.5 (d), 3.85 (bs, 6H), 4.28 (t, 1H), 7.06 (t, 1H), 7.19 (d, 2H), 7.65 (d, 2H), 7.86 (d, 2H), 8.08 (bs, 2H).

tert-Butyl [(1-*{(3R)*-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}piperidin-4-

5 yl)methyl]carbamate



tert-Butyl (piperidin-4-ylmethyl)carbamate (680 mg) [commercially available] was added to a solution of (3*R*)-3-(3,5-difluorophenyl)-3-(4-methanesulphonylphenyl)-

10 propionaldehyde (1g in 30 ml of dichloromethane prepared according to Method C) and sodium triacetoxyborohydride (671 mg) in dichloromethane (20 ml) and the mixture was stirred at room temperature for 3 hours then washed with 2M NaOH (2x50ml), dried and evaporated to dryness. The residue was passed down a Bond Elut column eluting with a


solvent gradient (ethyl acetate-20% methanol/ethyl acetate) to give the title compound, yield 1.6g, MH^+ 523. NMR (DMSO- d_6): 1.35 (s, 9H), 1.52 (d, 2H), 1.73 (d, 2H), 2.05-2.25 (m, 4H),

15 2.68-2.80 (m, 4H), 3.27 (s, 1H), 4.17 (t, 1H), 6.74 (m, 1H), 7.0 (t, 1H), 7.11 (d, 2H), 7.62

(d, 2H), 7.81 (d, 2H).

Example 2

This Example illustrates the preparation of *N*-[2-(1-*{(3R)*-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]-4-nitrobenzenesulfonamide (Compound 3 of Table III).




4-Nitrobenzenesulphonyl chloride (0.6 g) was added to a solution of [2-(1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)ethyl]amine (1.2g) (Method F) and pyridine (210 mg) in dichloromethane (50 ml) and the mixture was stirred for 2 hours, washed with water (2x25 ml) and dried. The residue obtained on removal of the solvent was purified by chromatography on silica eluting with a solvent gradient of ethyl acetate: 10% methanol/ethyl acetate to give the title compound, yield 1.6g, MH^+ 622, NMR ($CDCl_3$): 1.1-1.9 (m, 13H) 2.8 (m, 2H) 3.03 (m, 5H) 4.1 (m, 1H) 4.6 (Br, 1H) 6.6-6.8 (m, 3H) 7.4 (d, 2H) 7.9 (d, 2H) 8.05 (d, 2H) 8.35 (d, 2H).

Following this method but using [(1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]amine as starting material there is obtained *N*-[(1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]-4-nitrobenzenesulfonamide (Compound 5 Table II), MH^+ 608, NMR ($CDCl_3$): 1.1-1.9 (m, 11H) 2.8 (m, 2H) 2.9 (m, 2H) 3.05 (s, 3H) 4.1(t, 1H) 4.7 (m, 1H) 6.6-6.8 (m, 3H) 7.4 (d, 2H) 7.8 (d, 2H) 8.05 (d, 2H) 8.4 (d, 2H).

Example 3

This Example illustrates the preparation of 4-amino-*N*-[2-(1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)ethyl]benzenesulfonamide (Compound 4 in Table III)



A solution of *N*-[2-(1-((3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)ethyl]-4-nitrobenzenesulfonamide (1.4 g; Example 2) in a mixture of ethanol (100 ml) and THF (50 ml) containing 10% Pd/C (200 mg) as catalyst was hydrogenated at atmospheric pressure. The catalyst was filtered and the filtrate evaporated to dryness to give the title compound, yield 1.01 g, MH^+ 592, NMR ($CDCl_3$): 1.05-1.95 (m, 13H) 2.8 (m, 2H)


2.9 (q, 2H) 3.05 (s, 3H) 4.1 (m, 3H) 4.25 (m, 1H) 6.6-6.8 (m 5H) 7.4 (d, 2H) 7.6 (d, 2H) 7.9 (d, 2H).

Following this method but using *N*-[(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)methyl]-4-nitrobenzenesulfonamide as starting material there is obtained 4-amino-*N*-[(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)methyl]benzenesulfonamide (Compound 14 in Table II) MH^+ 578.

10

Example 4

This Example illustrates the preparation of *N*-[2-(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]-4-[(methylsulfonyl)amino]benzenesulfonamide (Compound 5 in Table III).




15

Methanesulphonyl chloride (77 mg) was added to a solution of 4-amino-*N*-[2-(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]benzenesulfonamide (0.4 g; Example 3) and triethylamine (53 mg) in dichloromethane (30 ml) and the mixture was stirred for 16 hours by which time an oil had precipitated out. Saturated aqueous sodium bicarbonate (100 ml) was added and the mixture was stirred for 20 minutes. The aqueous/dichloromethane mixture was decanted and the residue was stirred with water (25 ml) which was decanted in turn. The residue was dissolved in methanol (10 ml) and poured on to a 20g SCX2 cartridge which was eluted with methanol (5x20 ml) and 1M ammonia in methanol (5x20 ml). The methanolic ammonia washings were evaporated to dryness and the resulting glass was triturated with diethyl ether to give the title compound as a solid, yield 176 mg, MH^+ 670, NMR ($CDCl_3$): 1.1-1.9 (m, 13H) 2.75 (m, 2H) 2.95 (m, 2H) 3.05 (s, 3H) 3.1 (s, 3H) 4.1 (t, 1H) 4.6 (m, 1H) 6.6-6.8 (m, 3H) 7.3-7.5 (m, 4H) 7.8-7.9 (m, 4H).

Following this method but using 4-amino-*N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]benzenesulfonamide as starting material there is obtained *N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]-4-[(methylsulfonyl)amino]benzenesulfonamide (Compound 15 in Table II). MH^+ 656, NMR (DMSO_d₆): 1.3-1.9 (m, 11H) 2.6 (m, 2H) 2.8 (m, 2H) 3.1 (s, 3H) 3.15 (s, 3H) 4.2 (t, 1H) 7-7.2 (m, 3H) 7.3 (d, 2H) 7.6-7.9 (m, 6H)

Example 5


10 This Example illustrates the preparation of *N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]-4-[(trifluoromethyl)sulfonyl]amino]benzenesulfonamide (Compound 16 in Table II).



15 Trifluoromethanesulphonic anhydride (97 mg) was added to a solution of 4-amino-*N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]benzenesulfonamide (200 mg) in pyridine (5 ml) and the mixture was stirred for 2 hours. A further aliquot of trifluoromethanesulphonic anhydride was added and stirring continued for 16 hours. The solvent was evaporated and the oil obtained was stirred with water (25 ml). The water was decanted off and the oil dissolved in methanol (20 ml) and poured on to a 20g SCX2 cartridge and was eluted with methanol (6x20 ml) and 1M ammonia in methanol (8x20 ml). The methanolic ammonia washings were evaporated to dryness and the residue was stirred with dichloromethane (20 ml) for 20 minutes. The solid product was filtered and dried under vacuum, yield 40 mg MH^+ 710, NMR (DMSO_d₆): 1.3-1.9 (m, 11H) 2.6 (m, 2H) 2.8 (m, 2H) 3.15 (s, 3H) (4.2 (t, 1H) 7-7.2 (m, 5H) 7.3 (t, 1H) 7.4 (d, 2H) 7.6 (d, 2H) 7.9 (m, 2H)

Example 6

This Example illustrates the preparation of *N*-[(1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl*}*piperidin-4-yl)methyl]-4-nitrobenzenesulfonamide (Compound 2 in Table I).




5

4-Nitrobenzenesulphonyl chloride (0.61 g) was added to a stirred solution of [(1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl*}*piperidin-4-yl)methyl]amine (1.2 g; Method G) and triethylamine (282 mg) in dichloromethane (75 ml) and stirring was continued for 4 hours. The reaction mixture was washed with water (2x25 ml), dried and evaporated to dryness. The residue obtained on removal of the solvent was purified by chromatography on silica eluting with a solvent gradient of ethyl acetate: 20% methanol/ethyl acetate and gave the title compound, yield 1.2g, MH^+ 615, NMR ($CDCl_3$): 1.1-2.7 (m, 21H) 2.75 (s, 3H) 2.9 (t, 2H) 3.7 (m, 1H) 3.85 (m, 1H) 4.8 (m, 1H) 6.6 (m, 3H) 8.0 (d, 2H) 8.4 (d, 2H).

15

Example 7

This Example illustrates the preparation of 4-amino-*N*-[(1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl*}*piperidin-4-yl)methyl]benzenesulfonamide (Compound 3 in Table I).




20

A solution of *N*-[(1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methyl]-4-nitrobenzenesulfonamide (1 g) (Example 5) in THF (100 ml) containing 20% Pd(OH)₂/C as catalyst was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate was poured on to a 20g SCX2 cartridge and eluted with methanol (6x20 ml) and 1M ammonia in methanol (6x20 ml). The combined methanolic ammonia washings were evaporated to dryness to give the title compound, yield 1g, MH^+ 584, NMR (CDCl₃): 1.1-2.7(m, 21H) 2.75 (s, 3H) 2.8 (m, 2H) 3.7 (m, 1H) 3.9 (m, 1H) 4.1 (s, 2H) 4.4 (t, 1H) 6.6 (m, 5H) 7.6 (d, 2H)

10

Example 8

This Example illustrates the preparation of *N*-[4-*{*[1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methyl]amino]sulfonyl]phenyl]-acetamide (Compound 4 in Table I).




15

Acetic anhydride (86 mg) was added to a solution of 4-amino-*N*-[(1-*{*(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methyl]benzenesulfonamide (0.5 g; Example 6) and pyridine (67 mg) in dichloromethane (25 ml) and the mixture was stirred for 2 hours. An additional aliquot of acetic anhydride was added and stirring continued for 16 hours. The reaction mixture was washed with water (25 ml), dried and evaporated to dryness. The residue so obtained was purified by chromatography on silica eluting with a solvent gradient of ethyl acetate: 30% methanol/ethyl acetate and the product was obtained as a white solid after trituration with diethyl ether, yield 146 mg, MH^+ 626, NMR (CDCl₃): 1.1-2.1 (m, 17H) 2.2 (s, 3H) 2.3-2.6 (m, 3H) 2.7 (s, 3H) 2.8 (m, 2H) 3.7 (m, 1H) 3.8 (m, 1H) 6.6 (m, 3H) 7.6-7.8 (q, 4H) 7.9 (s, 1H).

25

Example 9

This Example illustrates the preparation of *N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl)piperidin-4-yl)methyl]-4-[(methylsulfonyl)amino]benzenesulfonamide (Compound 5 in Table I)




5

Methanesulphonyl chloride (90 mg) was added to a solution of 4-amino-*N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl)piperidin-4-yl)methyl]benzenesulfonamide (0.5 g; Example 6) and pyridine (67 mg) in dichloromethane (25 ml) and the mixture was stirred for 2 hours. An additional portion of methanesulphonyl chloride (30 mg) was added and stirring was continued for 16 hours. The solvent was removed and the residue was purified by chromatography on a 40g Biotage silica column eluting with a solvent gradient of ethyl acetate:25% methanol/ethyl acetate to give an oil which solidified on 10 trituration with diethyl ether, yield 421 mg, MH^+ 663, NMR ($CDCl_3$): 1.1-2.2 (m, 12H) 2.8 (s, 3H) 3.1 (s, 3H) 3.4 (m, 3H) 6.9-7.1 (m, 3H) 7.3 (d, 2H) 7.6 (t, 1H) 7.7 (d, 2H).

15

Example 10

This Example illustrates the preparation of *N*-[(1-((3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)piperidin-4-yl)methyl]-3-(1*H*-tetrazol-5-yl)benzenesulfonamide (Compound 18 in Table II)




20

Sodium azide (88 mg) and ammonium chloride (72 mg) were added to a solution of 3-cyano-*N*-[(1-*{(3R)*-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)methyl]benzenesulfonamide (400 mg) in DMF (20 ml) and the mixture was stirred and heated at 100 °C for 8 hours, evaporated to dryness and diluted with water (25 ml). The solid 5 product was dried under vacuum, yield 300 mg, MH^+ 631, NMR (DMSO d_6): 1.1-1.9 (m, 5H) 2.7 (m, 2H) 2.9 (m, 3H) 3.1 (s, 3H) 4.2 (t, 1H) 7.0-7.2 (m, 3H) 7.6-8 (m, 7H) 8.2 (m, 1H) 8.4 (s, 1H).

Example 11


10 This Example describes the preparation of *N*-[(1-*{(3R)*-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)methyl]-4-(1*H*-tetrazol-5-yl)-benzenesulfonamide (Compound 19 in Table II)



15 Sodium azide (154 mg) and ammonium chloride (127 mg) were added to a solution of 4-cyano-*N*-[(1-*{(3R)*-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)methyl]benzenesulfonamide (700 mg) in DMF (20 ml) and the mixture was stirred and heated at 100 °C for 8 hours, evaporated to dryness and diluted with water (25 ml). The solid product was dried under vacuum at 60 °C, yield 520 mg, MH^+ 631.


20 **Method A**

(*S*)-3-Phenyl-3-(4-methanesulfonylphenyl)propionaldehyde



Step 1: Preparation of (4*S*, 5*R*)-1-[(*S*)-3-(4-methanesulfonyl-phenyl)-3-phenyl-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one

35



To a mixture of copper (I) iodide (960mg, 5.0mmol) and THF (20mL) was added *N,N,N',N'*-tetramethylethylenediamine (0.83mL, 5.5mmol) and the resulting mixture was stirred at room temperature for 10min. then cooled to -78°C. Phenylmagnesium bromide (5.0mL, 1M in THF, 5.0mmol) was added and the resulting mixture stirred at -78°C for 15min. A solution of di-n-butylboron triflate (3.0mL, 1M in diethyl ether, 3.0mmol) and (*E*)-(4*S*, 5*R*)-1-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (step 4 below), 1.0g, 2.51mmol) in THF (15mL) was added and the resulting mixture was stirred whilst allowing to warm to room temperature for 18h. The reaction mixture was washed with saturated aqueous ammonium chloride, water and brine, dried (MgSO_4) and evaporated. The residue was purified by eluting through a 20g Bond Elut with gradient of isohexane to ethyl acetate giving the sub-titled compound (1.49g, 100%); NMR (CDCl_3): 0.78 (d, 3H), 2.82 (s, 3H), 3.00 (s, 3H), 3.78 (dd, 1H), 3.80 (m, 1H), 3.98 (dd, 1H), 4.72 (m, 1H), 5.19 (d, 1H), 6.99 (m, 2H), 7.22 (m, 8H), 7.48 (d, 2H), 7.79 (d, 2H); MS: 477 (MH^+).

15

Step 2: Preparation of (*S*)-3-phenyl-3-(4-methanesulphonylphenyl)propan-1-ol

To a solution of (4*S*, 5*R*)-1-[*(S*)-3-(4-methanesulphonyl-phenyl)-3-phenyl-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one (846mg, 1.78mmol) in THF (20mL) at 0°C was added lithium aluminium hydride (3.6mL, 1M in THF, 3.6mmol) and the resulting mixture was stirred for 15min. The reaction was quenched by the addition of 2M aqueous sodium hydroxide. The phases were separated and the organic phase pre-absorbed onto a Bond Elut and eluted with a gradient of isohexane to ethyl acetate giving the sub-titled compound as a white solid (285mg, 55%); NMR (CDCl_3): 1.63 (br s, 1H), 2.33 (m, 2H), 3.00 (s, 3H), 3.59 (t, 2H), 4.28 (t, 1H), 7.23 (m, 5H), 7.43 (d, 2H), 7.82 (d, 2H).

25


Step 3: Preparation of the title compound

36

To a solution of (*S*)-3-phenyl-3-(4-methanesulfonylphenyl)propan-1-ol (244mg, 0.84mmol) in DCM (5mL) was added Dess-Martin periodinane (392mg, 0.92mmol) and the resulting mixture was stirred at room temperature for 1.5h. The mixture was washed with 2M aqueous sodium hydroxide (2 x 10mL), dried and evaporated to give the title compound.


5

Step 4: Preparation of *E*-(4*S*, 5*R*)-1-(3-[4-Methanesulphonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one




To a stirred solution of 3-(4-methanesulphonylphenyl)acrylic acid (7.14g, 31.5mmol) in DCM (10mL) was added thionyl chloride (3mL, 34.7mmol) dropwise and the resulting mixture was stirred at room temperature for 18h. To this solution was added DIPEA (5.04mL, 28.9mmol) dropwise at room temperature. The resulting solution was added to a stirred solution of (4*R*, 5*S*)-1,5-dimethyl-4-phenyl-imidazolidin-2-one (5.0g, 26.3mmol) in DCM (20mL) and DIPEA (4.58mL, 26.9mmol) and the resulting mixture stirred at room temperature for 4h. The mixture was washed with water and brine, pre-absorbed onto a Bond Elut and eluted with a gradient of isohexane to ethyl acetate giving the title compound as a solid (7.61g, 73%); NMR (CDCl_3): 0.84 (d, 3H), 2.89 (s, 3H), 3.04 (s, 3H), 3.98 (m, 1H), 5.42 (d, 1H), 7.20 (m, 2H), 7.32 (m, 3H), 7.69 (d, 1H), 7.74 (d, 2H), 7.93 (d, 2H), 8.31 (d, 1H); MS: 399 (MH^+).

20




Method B

3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionaldehyde




Step 1 Preparation of 4-benzoyl-1-methanesulphonylpiperidine

37



Methanesulphonyl chloride was added to a stirred slurry of 4-benzoylpiperidine hydrochloride (4.51g) and triethylamine (8.35ml) in dichloromethane (100ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The 5 mixture was diluted with dichloromethane (50ml) and washed with ammonium chloride solution (2x25ml) and brine (25ml), dried and evaporated to dryness to give 4-benzoyl-1-methanesulphonylpiperidine as a white solid, yield 3.98g. NMR (CDCl₃): 1.93 (m, 4H), 2.81 (s, 3H), 2.98 (d-t, 2H), 3.40 (m, 1H), 3.77 (m, 2H), 7.43 (t, 2H), 7.57 (t, 1H), 7.89 (d, 2H).

10 Step 2 Preparation of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)acrylate.




Lithium bis(trimethylsilyl)amide (16.3ml of a 1M solution in THF) was added dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes. A slurry of 4-benzoyl-1-methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours. The reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml). The combined dichloromethane extracts were washed with brine (25ml), dried and evaporated to dryness. The residue was chromatographed on a 90g Biotage column eluted with a solvent gradient (30-5% ethyl acetate/iso hexane to give a less polar fraction (1.62g) and a more polar fraction (0.53g). Both fractions (cis/trans isomers) were combined and used for the next step.

Less polar NMR (CDCl₃): 1.27 (t, 3H), 1.69 (m, 2H), 1.81 (d, 2H), 2.72 (s, 3H), 2.72 (t, 2H), 3.81 (d, 2H), 3.88 (m, 1H), 4.21 (q, 2H), 5.78 (s, 1H), 7.11 (m, 2H), 7.27 (m, 3H).

More polar NMR (CDCl_3): 1.01 (t, 3H), 1.56 (m, 2H), 1.85 (d, 2H), 2.31 (m, 1H), 2.63 (t, 2H), 2.74 (s, 3H), 3.83 (d, 2H), 3.92 (q, 3H), 5.82 (s, 1H), 7.04 (d, 2H), 7.30 (m, 3H).

Step 3 Preparation of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate




5

A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)acrylate (2.06g) in ethanol (30ml) was hydrogenated over 24 hours under a hydrogen filled balloon using 20% palladium hydroxide as catalyst. The reaction mixture was filtered through Celite and the filtrate evaporated to dryness. The product obtained was used for the next step without further

10

purification. $\text{MH}^+ 340$.


Step 4 3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propan-1-ol.



A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate (2g) in THF (10ml) was added to a suspension of lithium aluminium hydride (232mg) in THF (20ml) at 0°C under argon over 30 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 2 hours. Water (10ml) was added followed by magnesium sulphate (10g). The reaction mixture was filtered and the filtrate evaporated to dryness to give the product as a white foam, yield 1.57g. NMR (CDCl_3): 1.40 (m, 4H), 1.57 (m, 1H), 1.78 (m, 1H), 2.01 (m, 2H), 2.45 (m, 2H), 2.58 (t, 1H), 2.70 (m, 3H), 3.31 (m, 1H), 3.42 (m, 1H), 3.67 (d, 1H), 3.80 (d, 1H), 7.04 (d, 1H), 7.19 (t, 1H), 7.29 (q, 2H).

Step 5 Preparation of the title compound


39



Dess-Martin periodinane (739mg) was added to a stirred solution of 3-phenyl-3-(N-methanesulfonylpiperidin-4-yl)propan-1-ol (454mg) in dichloromethane (8ml) and stirring was continued for 2 hours. The reaction mixture was diluted with dichloromethane (100ml) 5 and washed with 2M sodium hydroxide (2x50ml), brine (50ml) and dried. The product obtained on removal of the solvent was used in subsequent steps without purification.

Method C

(R)-3-(3,5-Difluorophenyl)-3-(4-methanesulfonylphenyl)propionaldehyde




10

This was prepared from (4S, 5R)-1-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one and 3,5-difluorophenylmagnesium bromide using a method similar to that used to prepare (S)-3-phenyl-3-(4-methanesulfonylphenyl)propionaldehyde from phenylmagnesium bromide (Method A); NMR (CDCl₃): 3.05 (s, 3H), 3.20 (d, 2H), 4.72 (t, 1H), 6.75 (m, 3H), 7.35 (d, 2H), 7.88 (d, 2H), 9.75 (s, 1H).

Method D


(R) 3-(1-Methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde



20


Step 1 3-[N-(benzyloxycarbonylpiperidin-4-yl)]propenoic acid

40



A mixture of N-benzyloxycarbonyl-4-formylpiperidine (10g), malonic acid (4.2), pyridine (4 ml) and piperidine (0.4 ml) was heated at 100°C for 2 hours. The reaction mixture was allowed to cool and was diluted with ethyl acetate (100 ml). The solution was washed 5 with 2M HCl (2X100 ml), dried and evaporated to dryness. The residue was triturated with isohexane to give the title compound, yield 13.5g. NMR (DMSO_d6) : 1.2 (m, 2H) 1.7 (m, 2H) 2.35 (m, 1H) 2.85 (m, 2H) 4 (d, 2H) 5.05 (s, 2H) 5.75 (d, 1H) 6.75 (m, 1H) 7.35 (m, 5H) 12.25 (broad peak, 1H)


10 Step 2 N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid isopropyl ester



A solution of N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid (52g) in isopropanol (500 ml) containing concentrated sulphuric acid (20 ml) was heated under reflux for 32 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate (250 ml). The ethyl 15 acetate solution was washed with water (2X250 ml) and saturated aqueous sodium bicarbonate (2X25 ml) and dried. The residue obtained on evaporation of the solvent was chromatographed on a Bond Elut cartridge eluted with a solvent gradient (isohexane-25% ethyl acetate/isohexane) to give the title compound, yield 54g.

20 Step 3 Preparation of (R) 3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester


41



Dioxane (100 ml) was charged to a 500 ml three necked flask and purged with argon for 10 minutes. Acetylacetonatobis[ethylene]rhodium (I) (620 mg) and R-BINAP were added and the mixture was stirred for 10 minutes. 3,5-Difluorophenylboronic acid (19g) was added


5 and the mixture was purged with argon for 10 minutes. N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid isopropyl ester (8 g) and ethanediol (20 ml) in dioxane (100 ml) were added and the mixture was purged with argon for 10 minutes. The mixture was heated at 100°C for 18 hours, allowed to cool and was passed through activated alumina (200g) washed through with ethyl acetate (3X100 ml). The combined washings were evaporated to dryness and the residue obtained was dissolved in ethyl acetate (100 ml) and washed successively with saturated aqueous sodium bicarbonate (2X100 ml) and 2M HCl (2X100 ml), dried and evaporated to dryness. The product obtained (12g) was shown to be 40% of the required material by NMR and was used without further purification in the subsequent reactions.

10 15 Step 4 Preparation of (R) 3-(piperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester.



20 A solution of (R) 3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (12g) in ethanol (300 ml) containing 20% palladium hydroxide on charcoal (2g) was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate was evaporated to dryness to give the title compound (10g) which was used without further purification.


Step 5 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)-propanoic acid isopropyl ester.



5 Methanesulphonyl chloride (3.7g) was added to a solution of (R) 3-(piperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (10g) and triethylamine (3.89g) in dichloromethane (100 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was washed with 2M HCl (2X50 ml) and saturated aqueous sodium bicarbonate (2X50 ml), dried and evaporated to dryness to give the title compound (10g) which was used without further purification.

10

Step 6 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanol




15 Lithium aluminium hydride (25 ml of a 1M solution in THF) was added dropwise over 15 minutes to a solution of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (10g) in THF (150 ml) at -10°C. The reaction mixture was stirred at -10°C for 30 minutes, 2M NaOH (25 ml) was added, the mixture was filtered and the filtrate evaporated to dryness. The residue obtained was dissolved in ethyl acetate and washed with 2M HCl (2X100 ml) and dried. The residue obtained on removal of the solvent was chromatographed on a Bond Elut column eluting with a solvent gradient (80% ethyl acetate/isohexane-ethyl acetate) to give the title compound, yield 2.2 g. NMR

20

(Dimethylsulfoxide d6): 0.95-1.2 (m, 2H) 1.3 (m, 1H) 1.6 (m, 2H) 1.9 (m, 2H) 2.6 (m, 2H) 2.8 (s, 3H) 3.1 (m, 1H) 3.2 (m, 1H) 3.4 (m, 1H) 3.5 (m, 1H) 6.8-7 (m, 3).

Step 7 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propionaldehyde.

5




Dess-Martin periodinane (1g) was added to a solution of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanol (0.8g) in dichloromethane (40 ml) and the mixture was stirred for 1.5 hours. The reaction mixture was washed with 2M


10 NaOH (2X20 ml) and dried. The solution of the title compound in dichloromethane was used in subsequent reactions.

Method E

(R) 3-(N-methanesulphonylpiperidin-4-yl)-3-phenylpropanol



Step 1 Preparation of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid acid chloride.




1-Chloro-N,N,2-trimethylpropenylamine (1.06 ml) was added dropwise over 10 minutes to a suspension of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid (1.86g, prepared from N-methanesulphonylpiperidine-4-carboxaldehyde [CAS 241134-35-0]

20


according to step 1 of Method C) in THF (20 ml) under an atmosphere of argon and the mixture was stirred for 2 hours and used directly in step 2.

Step 2 Preparation of 1-[3-(N-methanesulphonylpiperidin-4-yl)propenyl]-(4S, 5R)-3,4-dimethyl-4-phenyl-imidazolidin-2-one.



Lithium bis(trimethylsilyl)amide (8 ml of a 1M solution in THF) was added dropwise to a suspension of (4R,5S)-1,5-dimethyl-4-phenyl-2-imidazolidinone (1.52g) in THF (20 ml) under argon at -10°C. the reaction mixture was stirred at -10°C for 10 minutes, allowed to 10 warm to 0°C and maintained at this temperature for 10 minutes then cooled again to -10°C. The solution of the acid chloride prepared in Step 1 was added dropwise and the reaction mixture was allowed to warm to room temperature and washed with water (100 ml). The aqueous extract was extracted with ethyl acetate (3X50 ml) and the ethyl acetate extracts were dried and the residue passed through a 90g Biotage column eluting with a solvent gradient 15 (50% ethyl acetate/isohexane-70% ethyl acetate/isohexane). Yield 1.89g. LC-MS MH^+ 406, NMR ($CDCl_3$) : 0.8 (d, 3H) 1.5-1.6 (m, 3H) 1.9 (m, 2H) 2.3 (m, 1H), 2.7 (m, 2H) 2.75 (s, 3H) 2.8 (s, 3H) 3.75 (m, 2H) 3.9 (m, 1H) 5.3 (d, 1H) 6.85 (d-d, 1H) 7.1 (d, 1H) 7.2-7.35 (m, 3H) 7.45 (d, 1H).

20 Step 3 Preparation of (R) 1-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]-(4S,5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one.



A mixture of copper(I) iodide (1.78 g) and *N,N,N',N'*-tetramethylethylenediamine (1.41 ml) in THF (50 ml) was stirred under argon for 1 hour then cooled to -78°C and


phenylmagnesium bromide (5.4 ml of a 1M solution in THF) was added and the mixture was stirred at -78°C for 30 minutes. A solution of 1-[3-(N-methanesulphonylpiperidin-4-yl)propenyl]-(4S, 5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.89g) and dibutylboron triflate (4.67 ml of a 1M solution in diethylether in THF (50 ml) was added over 10 minutes and the reaction mixture was stirred at -78°C for 1 hour then allowed to warm to room temperature. The reaction mixture was concentrated and filtered through a pad of silica (50g) washed with ethyl acetate (2X50 ml) and the ethyl acetate washings were washed with 2M HCl (2X150 ml) and dried. The residue obtained on removal of the solvent was passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane-10 70% ethyl acetate/isohexane) to give the product as a yellow solid, yield 1.34g, MH^+ 484. NMR ($CDCl_3$) : 0.7 (d, 3H) 1.2 (m, 1H) 1.35 (m, 1H) 1.5 (m, 1H) 1.9 (m, 1H) 2.45 (m, 1H) 2.55 (m, 1H) 2.7 (s, 3H) 2.8 (s, 3H) 3.1 (m, 1H) 3.2 (d-d, 1H) 3.4 (m, 1H) 3.65 (m, 1H) 3.75-3.9 (m, 3H) 5.2 (d, 1H) 6.7 (d, 2H) 7.05-7.25 (m, 8H).

15 Step 4 Preparation of the title compound

A solution of (R) 1-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]-(4S,5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.34g) in THF (14 ml) was added to a solution of lithium aluminium hydride (2.77 ml of a 1M solution in THF) in THF (10 ml) at 0°C and the mixture was allowed to warm to room temperature over 1 hour. Water (5 ml) was added 20 cautiously, then THF (15 ml) and solid magnesium sulphate. The reaction mixture was filtered and the filtrate was passed through a 40 g Biotage column eluted with a solvent gradient (50% ethyl acetate/isohexane-70% ethyl acetate/isohexane) to give the title compound as a white solid, yield 338 mg. NMR ($CDCl_3$) : 1.15-1.25 (m, 2H) 1.3-1.5 (m, 2H) 1.6 (m, 1H) 1.75 (m, 1H) 1.95-2.10 (m, 2H) 2.5 (m, 2H) 2.6 (m, 1H) 2.7 (s, 3H) 3.3-3.4 (m, 2H) 3.45 (m, 1H) 3.7 (m, 1H) 3.85 (m, 1H) 7.05 (m, 2H) 7.15-7.35 (m, 3H).

Method F

(S) 3-phenyl-3-(*tert*-butoxycarbonylamino)propionaldehyde




Lithium aluminium hydride (19 ml of 1M solution in THF) was added to a solution of (S) 3-phenyl-3-(tert-butoxycarbonylamino)propionic acid (5.01g) in THF (50ml) at 0°C. The reaction mixture was stirred for 1 hour and ethyl acetate (20ml) was added followed by water (0.5ml), 6M sodium hydroxide (0.5ml) and water (5ml). The mixture was filtered through

5 Celite and evaporated to dryness to give (S) 3-phenyl-3-(tert-butoxycarbonylamino)propanol, yield 2.89g. This material was dissolved in dichloromethane (40ml) and Dess Martin periodinane (2.12g) was added. The reaction mixture was stirred for 1 hour then washed with 2M sodium hydroxide (2x20ml) and brine (10ml) and dried. The dichloromethane solution was concentrated to a volume of about 20ml and used directly in the next stage.


10

Method G

Preparation of 1-(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methanamine



15 Step 1 Preparation of *tert*-butyl [(1-{(3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methyl]carbamate



20 Sodium triacetoxyborohydride (1.26 g) was added to a solution of (3*R*)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanal (2.0 g) and *tert*-butyl (piperidin-4-ylmethyl)carbamate (1.26 g) in dichloromethane (75 ml) and the mixture was stirred for 4 hours then washed with 2M NaOH (2x50 ml), dried and evaporated to dryness. The residue obtained on removal of the solvent was purified by chromatography on silica eluting with a


solvent gradient of ethyl acetate: 20% methanol/ethyl acetate. The oily product obtained gave a solid on trituration with diethyl ether, yield 3g, MH^+ 530.

Step 2 Preparation of the title compound


5 A solution of *tert*-butyl (piperidin-4-ylmethyl)carbamate (3 g) in 4M HCl in dioxane (25 ml) and methanol (5 ml) was stirred for 2 hours. Diethyl ether (100 ml) was added and the solid obtained on filtration was dissolved in water (50 ml). The aqueous solution was basified with 2M NaOH and extracted with dichloromethane (5x25 ml). The combined dichloromethane extracts were dried and the gum obtained on removal of the solvent was 10 stirred with diethyl ether to give the title compound as a white solid, yield 2.1g, MH^+ 429. NMR ($CDCl_3$): 1.1-2.7 (m, 21H) 2.75 (s, 3H) 2.9 (m, 2H) 3.6-3.9 (m, 4H) 6.6 (m, 3H).

Method H

Preparation of [2-(1- $\{(3R)\text{-}3\text{-}(3,5\text{-difluorophenyl})\text{-}3\text{-[4-(methylsulfonyl)phenyl]propyl}\}\text{-}15$ piperidin-4-yl)ethyl]amine



Step 1 Preparation of *tert*-butyl [2-(1- $\{(3R)\text{-}3\text{-}(3,5\text{-difluorophenyl})\text{-}3\text{-[4-(methylsulfonyl)phenyl]propyl}\}\text{-}15$ piperidin-4-yl)ethyl]carbamate



20 Sodium triacetoxyborohydride (2.78 g) was added to a solution of (3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propanal (4.2 g) and *tert*-butyl 4-piperidin-4-ylbutanoate (3 g) in dichloromethane (100 ml) and the mixture was stirred for 16 hours. The

reaction mixture was washed with 2M NaOH (2x50 ml), dried and poured onto a 50g SCX2 cartridge and eluted with methanol (5x20 ml) and 1M ammonia in methanol (6x20 ml). The methanolic ammonia washings were evaporated to dryness to give *tert*-butyl [2-(1-[(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]piperidin-4-yl)ethyl]carbamate,

5 yield 5.6g, MH^+ 537, NMR ($CDCl_3$): 1.3 (m, 3H) 1.4 (m, 5H) 1.45 (s, 9H) 1.7 (m, 3H) 1.85 (m, 2H) 2.7 (m, 2H) 3.05 (s, 3H) 3.15 (m, 2H) 4.1 (m, 1H) 4.4 (Br m, 1H) 6.6-6.8 (m, 3H) 7.4 (d, 2H) 7.9 (d, 2H)

Step 2 Preparation of the title compound

10 4M HCl in dioxane (40 ml) was added to a paste of *tert*-butyl [2-(1-[(3*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]piperidin-4-yl)ethyl]carbamate (5.6 g) in dioxane (5 ml) and the mixture was stirred for 1.5 hours. The solid was filtered and dissolved in water (50 ml). The aqueous solution was basified with 2M NaOH and was extracted with dichloromethane (5x50 ml). The combined extracts were dried and evaporated to dryness to 15 give the title compound, yield 4.2g, MH^+ 437, NMR ($CDCl_3$): 1.1-1.5 (m, 9H) 1.7 (d, 2H) 1.9 (t, 2H) 2.7 (t, 2H) 2.8 (m, 2H) 3.05 (s, 3H) 4.1 (m, 1H) 6.6-8 (m, 3H) 7.4 (d, 2H) 7.9 (d, 2H).

Example 12

20 The ability of compounds to inhibit the binding of MIP-1 α was assessed by an *in vitro* radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated with 0.1nM iodinated MIP-1 α , scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated MIP-1 α bound to the receptor was determined by scintillation counting. Competition curves were obtained for 25 compounds and the concentration of compound which displaced 50% of bound iodinated MIP-1 α was calculated (IC_{50}). Certain compounds of formula (I) have an IC_{50} of less than 50 μ M.


Results from this test for certain compounds of the invention are presented in Table IV. In Table IV the results are presented as Pic50 values. A Pic50 value is the negative log (to base 10) of the IC_{50} result, so an IC_{50} of 1 μ M (that is 1×10^{-6} M) gives a Pic50 of 6. If a compound was tested more than once then the data below is an average of the probative tests results.

TABLE IV

Table Number	Compound number	Pic50
I	1	9.3
I	4	8.1
I	7	8.3
II	6	6.8
II	12	7.7
II	13	8.0
II	16	7.3
II	19	8.1
III	2	6.8

Scheme 1

To prepare compounds of the invention, for example wherein R¹ is aryl or C-linked piperidine.



5


i Wittig reaction (eg LHDMS, triethylphosphonoacetate)

ii Catalytic hydrogenation (eg H₂, 10% Pd/C)

iii Reduction (eg LAH)

iv Oxidation (eg Dess-Martin oxidation)


10

v reductive amination with  (eg using sodium triacetoxyborohydride)

101146-2 SB


Scheme 2

To prepare compounds of the invention, for example wherein R¹ is aryl or C-linked piperidine.




5

i Base hydrolysis (eg LiOH, MeOH/H₂O)ii MeMgCl, R³MgBr, Et₂O

iii reductive amination  in presence of titanium tetra-isopropoxide (eg using sodium triacetoxyborohydride)

Scheme 3


To prepare compounds of the invention, for example wherein R¹ is aryl, heteroaryl, heterocyclyl or NR¹³C(O)R¹⁴.



5 in which L is an activated group, such as halogen, mesylate, tosylate or triflate.

Scheme 4


To prepare compounds of the invention, for example wherein R¹ is aryl, heteroaryl, heterocyclyl or NR¹³C(O)R¹⁴.



in which L¹ is a halogen, an activated ester or a complex formed with a carbodiimide.

Scheme 5

To prepare compounds of the invention, for example wherein R^1 is $NR^{13}C(O)R^{14}$.




i reductive amination (if R^3 is H can use sodium triacetoxyborohydride; if R^3 is alkyl
 5 can use titanium tetra-isopropoxide and sodium triacetoxyborohydride)

ii Deprotection (eg TFA)


iii amide bond formation (eg acid chloride, active ester or carbodiimide mediated)

Scheme 6

To prepare compounds of the invention, for example wherein R¹ is piperazine.



5 i Conversion of an OH to a leaving group (eg tosyl chloride (L² is Tosylate) or mesyl chloride (L² is Mesylate))

ii displacement reaction with  (eg in presence of triethylamine)

iii Mesyl chloride, DCM 0°C

iv Displacement reaction with mono-protected piperazine (P is a protecting group)


v Displacement reaction with R substituted piperazine

vi Deprotection (TFA for Boc, hydrogenation for Cbz)

vii Depending on R, acylation, sulphonylation, reductive amination

Scheme 7


To prepare compounds of the invention, for example wherein R¹ is aryl or piperidine.



i activation of acid group and coupling with chiral auxiliary (eg SOCl_2 ,
 ii 1,4-addition of organocuprate (eg R^2MgBr , $\text{Cu}(\text{I})\text{I}$, TMEDA, di-butylboron triflate)
 iii reduction (eg lithium aluminium hydride)
 iv Dibal
 v Oxidation (eg Dess-Martin reagent)
 vi reductive amination (eg with sodium triacetoxyborohydride)

Scheme 8

To prepare compounds of the invention wherein X is $S(O)_2NR^4R^5$.



5

i activation via halide, tosylate, mesylate, triflate

ii thiolacetic acid, base

iii sodium sulphite, sodium iodide

iv chlorine, acetic acid

v Chlorinating agent (e.g., PCl_5)


vi NHR^4R^5 , base

10

57


Scheme 9

To prepare compounds of the invention wherein X is $\text{NR}^6\text{S(O)}_2\text{NR}^7$.

10
09
08
07
06

CLAIMS

1. A compound of formula (I):



5

wherein:

A is absent or is $(CH_2)_2$;

R^1 is $C(O)NR^{10}R^{11}$, $C(O)_2R^{12}$, $NR^{13}C(O)R^{14}$, $NR^{15}C(O)NR^{16}R^{17}$, $NR^{18}C(O)_2R^{19}$, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl, cycloalkyl or heteroaryl;

10 R^{10} , R^{13} , R^{15} , R^{16} and R^{18} are hydrogen or C_{1-6} alkyl;

R^{11} , R^{12} , R^{14} , R^{17} and R^{19} are C_{1-8} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl (optionally substituted by halo), C_{5-6} cycloalkenyl, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C_{3-7} cycloalkyl (optionally substituted by halo or C_{1-4} alkyl), C_{4-7} cycloalkyl fused to a phenyl ring, C_{5-7} cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, $C(O)(C_{1-6}$ alkyl), $S(O)_k(C_{1-6}$ alkyl), halo or C_{1-4} alkyl); or R^{11} , R^{12} , R^{14} and R^{17} can also be hydrogen;

15 or R^{10} and R^{11} , and/or R^{16} and R^{17} may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C_{1-6} alkyl, $S(O)_l(C_{1-6}$ alkyl) or $C(O)(C_{1-6}$ alkyl);

20 R^2 is phenyl, heteroaryl or C_{3-7} cycloalkyl;

R^3 is H or C_{1-4} alkyl;

25 X is $S(O)_2NR^4R^5$ or $NR^6S(O)_2R^7$;

R^7 is aryl, heteroaryl, C_{1-6} alkyl, C_{3-7} cycloalkyl, heterocyclyl or NR^8R^9 wherein NR^8R^9 can be cyclized to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C_{1-6} alkyl, $S(O)_p(C_{1-6}$ alkyl) or $C(O)(C_{1-6}$ alkyl);

30 R^4 and R^8 are aryl, heteroaryl, C_{1-6} alkyl, C_{3-7} cycloalkyl or heterocyclyl;

R^5 , R^6 and R^9 are, independently, hydrogen or C_{1-6} alkyl;

n is 1, 2 or 3;

aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, $\text{OC(O)NR}^{20}\text{R}^{21}$, $\text{NR}^{22}\text{R}^{23}$, $\text{NR}^{24}\text{C(O)R}^{25}$, $\text{NR}^{26}\text{C(O)NR}^{27}\text{R}^{28}$, $\text{S(O)}_2\text{NR}^{29}\text{R}^{30}$, $\text{NR}^{31}\text{S(O)}_2\text{R}^{32}$, $\text{C(O)NR}^{33}\text{R}^{34}$, CO_2R^{36} , $\text{NR}^{37}\text{CO}_2\text{R}^{38}$, $\text{S(O)}_q\text{R}^{39}$, $\text{OS(O)}_2\text{R}^{49}$, C_{1-6} alkyl (optionally mono-substituted by $\text{S(O)}_2\text{R}^{50}$ or $\text{C(O)NR}^{51}\text{R}^{52}$), C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)₂, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, $\text{S(C}_{1-4}\text{ alkyl)}$, $\text{S(O)(C}_{1-4}\text{ alkyl)}$, $\text{S(O)}_2\text{(C}_{1-4}\text{ alkyl)}$, $\text{S(O)}_2\text{NH}_2$, $\text{S(O)}_2\text{NH(C}_{1-4}\text{ alkyl)}$, $\text{S(O)}_2\text{N(C}_{1-4}\text{ alkyl)}_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C(O)NH_2 , $\text{C(O)NH(C}_{1-4}\text{ alkyl)}$, $\text{C(O)N(C}_{1-4}\text{ alkyl)}_2$, CO_2H , $\text{CO}_2\text{(C}_{1-4}\text{ alkyl)}$, $\text{NHC(O)(C}_{1-4}\text{ alkyl)}$, $\text{NHS(O)}_2\text{(C}_{1-4}\text{ alkyl)}$, CF_3 or OCF_3 ;

unless otherwise stated heterocyclyl is optionally substituted by C_{1-6} alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3 , OCF_3 , $(\text{C}_{1-4}\text{ alkyl})\text{C(O)NH}$, $\text{S(O)}_2\text{NH}_2$, C_{1-4} alkylthio, $\text{S(O)(C}_{1-4}\text{ alkyl)}$ or $\text{S(O)}_2\text{(C}_{1-4}\text{ alkyl)}$ } or heteroaryl {which itself optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3 , $(\text{C}_{1-4}\text{ alkyl})\text{C(O)NH}$, $\text{S(O)}_2\text{NH}_2$, C_{1-4} alkylthio, $\text{S(O)(C}_{1-4}\text{ alkyl)}$ or $\text{S(O)}_2\text{(C}_{1-4}\text{ alkyl)}$ }], phenyl {optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3 , OCF_3 , $(\text{C}_{1-4}\text{ alkyl})\text{C(O)NH}$, $\text{S(O)}_2\text{NH}_2$, C_{1-4} alkylthio, $\text{S(O)(C}_{1-4}\text{ alkyl)}$ or $\text{S(O)}_2\text{(C}_{1-4}\text{ alkyl)}$ }, heteroaryl {optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3 , $(\text{C}_{1-4}\text{ alkyl})\text{C(O)NH}$, $\text{S(O)}_2\text{NH}_2$, C_{1-4} alkylthio, $\text{S(O)(C}_{1-4}\text{ alkyl)}$ or $\text{S(O)}_2\text{(C}_{1-4}\text{ alkyl)}$ }, $\text{S(O)}_2\text{NR}^{40}\text{R}^{41}$, C(O)R^{42} , $\text{C(O)}_2\text{(C}_{1-6}\text{ alkyl)}$ (such as tert-butoxycarbonyl), $\text{C(O)}_2\text{(phenyl(C}_{1-2}\text{ alkyl))}$ (such as benzyloxycarbonyl), C(O)NHR^{43} , $\text{S(O)}_2\text{R}^{44}$, $\text{NHS(O)}_2\text{NHR}^{45}$, NHC(O)R^{46} , NHC(O)NHR^{47} or $\text{NHS(O)}_2\text{R}^{48}$, provided none of these last four substituents is linked to a ring nitrogen;

k , l , p and q are, independently, 0, 1 or 2;

R^{20} , R^{22} , R^{24} , R^{26} , R^{27} , R^{29} , R^{31} , R^{33} , R^{37} , R^{40} and R^{51} are, independently, hydrogen or C_{1-6} alkyl;

R^{21} , R^{23} , R^{25} , R^{28} , R^{30} , R^{32} , R^{34} , R^{36} , R^{38} , R^{39} , R^{41} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{47} , R^{48} , R^{49} , R^{50} and R^{52} are, independently, C_{1-6} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} cycloalkenyl, $\text{S(C}_{1-4}\text{ alkyl)}$, S(O)(C_{1-

4 alkyl), S(O)₂(C₁₋₄ alkyl), heteroaryl, phenyl, heteroaryloxy or phenoxy), C₃₋₇ cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;
5 R²¹, R²³, R²⁵, R²⁸, R³⁰, R³⁴, R³⁵, R³⁶, R⁴¹, R⁴², R⁴³, R⁴⁵, R⁴⁶, R⁴⁷ and R⁵² may
additionally be hydrogen;
10 or a pharmaceutically acceptable salt thereof or a solvate thereof.


2. Processes for preparing a compound as claimed in claim 1.
3. A pharmaceutical composition which comprises a compound as claimed in claim 1, or
15 a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
4. A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.
- 20 5. A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.
- 25 6. A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.

61

ABSTRACTCHEMICAL COMPOUNDS

Compounds of formula (I):

5



wherein R^1 , R^2 , R^3 , A , X and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).